Moleculin Biotech Achieves Full Part A Enrollment in Phase 2/3 AML MIRACLE Trial

With 89 subjects enrolled and Part A now closed, Moleculin Biotech has set a firm Q1 2027 clock on the MIRACLE trial's comprehensive data readout, a timeline that CMO partners and GMP drug supply planners supporting R/R AML indications should be tracking now. The pivotal Phase 2/3 study evaluates Annamycin in combination with cytarabine (AnnAraC) in adults with relapsed or refractory acute myeloid leukemia.

Enrollment velocity in a global, randomized oncology trial of this complexity signals meaningful investigator engagement and site-level operational discipline. For clinical supply teams, the closed enrollment window narrows the demand uncertainty window and moves the program into the data maturation phase, where blinded sample integrity and chain-of-custody controls become the operative GMP concern.

The expanded Part A dataset is expected to approximate a 50/50 distribution between subjects previously treated with intensive 7+3 chemotherapy and those treated with venetoclax-based regimens, a shift from the roughly 70/30 fit-to-unfit split observed in the first 45 subjects. That compositional change introduces a more clinically challenging population into the efficacy analysis, as venetoclax-refractory patients are broadly considered harder to treat. The broader split, however, should yield more granular response data across distinct prior-treatment lines, which carries direct relevance for any future label language and post-approval REMS or risk management considerations.

On the safety side, the absence of cardiotoxicity in MIRACLE's blinded data continues to differentiate Annamycin from conventional anthracyclines. Cardiotoxicity monitoring has historically driven significant protocol amendment activity and site-level burden in anthracycline-based regimens; a clean signal here, if confirmed in the unblinded readout, would simplify pharmacovigilance planning and potentially reduce the cardiac monitoring requirements that typically accompany anthracycline labeling under 21 CFR Part 312 IND safety reporting frameworks.

The Q1 2027 comprehensive readout will represent a substantially deeper dataset than the earlier interim n45 analysis, providing the statistical weight needed to support any subsequent NDA or BLA submission pathway discussions with FDA. Regulatory affairs leads at organizations monitoring the R/R AML competitive landscape should note that a positive readout would accelerate Moleculin's transition from development-stage to pre-submission activities, with attendant implications for manufacturing scale-up, process validation, and CMO capacity allocation.

The next measurable checkpoint is the Q1 2027 Part A data readout, at which point efficacy signals across fit and unfit patient populations will either support or complicate the program's path to a registration-enabling dataset.

Source: Moleculin Biotech, Inc. via GlobeNewswire, September 29, 2026.